Creative Medical Technology (NASDAQ:CELZ) Stock Passes Below Fifty Day Moving Average – Should You Sell?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.24 and traded as low as $2.21. Creative Medical Technology shares last traded at $2.23, with a volume of 96,464 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a report on Friday, May 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.

Creative Medical Technology Price Performance

The company’s fifty day moving average price is $2.24 and its 200 day moving average price is $2.09. The company has a market capitalization of $8.24 million, a P/E ratio of -1.04 and a beta of 1.84.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.01. Research analysts predict that Creative Medical Technology Holdings, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.